atrasentan has been researched along with Pain in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, KW; de Zeeuw, D; Gansevoort, RT; Heerspink, HJL; Jongs, N; Kohan, DE; Liew, A; Schechter, M; Smeijer, JD; Tang, SCW; Vart, P; Wanner, C | 1 |
| Iwagami, M | 1 |
| Garber, K | 1 |
| Lee, D | 1 |
| Fujimori, A; Fujiyasu, N; Koakutsu, A; Miyata, K; Sasamata, M; Sato, S; Shibasaki, K; Sudoh, K; Tanahashi, M; Tanaka, S; Yuyama, H | 1 |
| Ghilardi, JR; Lindsay, TH; Luger, NM; Mantyh, PW; Peters, CM; Pomonis, JD; Sevcik, MA | 1 |
| Clines, GA; Guise, TA | 1 |
| Chichorro, JG; Rae, GA; Zampronio, AR | 1 |
| Calzadilla, SV; Dayton, BD; Jarvis, MF; Kowaluk, EA; Lynch, JJ; Opgenorth, TJ; Padley, RJ; Wessale, JL; Zhu, CZ | 1 |
1 review(s) available for atrasentan and Pain
| Article | Year |
|---|---|
Mechanisms and treatment for bone metastases.
Topics: Animals; Atrasentan; Bone Neoplasms; Cell Adhesion Molecules; Cytokines; Diphosphonates; Endothelin-1; Female; Gene Expression Regulation, Neoplastic; Humans; Hypercalcemia; Immunotherapy; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Nude; Neoplasm Proteins; Osteoblasts; Osteolysis; Pain; Pain Management; Pyrrolidines; Xenograft Model Antitumor Assays | 2004 |
2 trial(s) available for atrasentan and Pain
| Article | Year |
|---|---|
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelin Receptor Antagonists; Humans; Pain; Renal Insufficiency, Chronic | 2023 |
Clinical trials of atrasentan in hormone-refractory prostate cancer.
Topics: Atrasentan; Disease Progression; Double-Blind Method; Endothelin-1; Humans; Male; Neoplasm Metastasis; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Survival Analysis; Treatment Outcome | 2003 |
6 other study(ies) available for atrasentan and Pain
| Article | Year |
|---|---|
Post hoc analysis of the SONAR trial: potential analgesic effects of atrasentan?
Topics: Atrasentan; Cognition; Diabetic Nephropathies; Humans; Pain; Prospective Studies | 2023 |
Why it hurts: researchers seek mechanisms of cancer pain.
Topics: Acidosis; Analgesics; Animals; Antineoplastic Agents; Atrasentan; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Glycoproteins; Humans; Ion Channels; Neoplasms; Osteoprotegerin; Pain; Pyrrolidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor | 2003 |
Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain.
Topics: Analgesics, Non-Narcotic; Animals; Atrasentan; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Hindlimb; Male; Mice; Mice, SCID; Pain; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Sulfonamides; Time Factors; Viper Venoms | 2004 |
Endothelin and the tumorigenic component of bone cancer pain.
Topics: Analysis of Variance; Animals; Atrasentan; Behavior, Animal; Bone Neoplasms; Calcitonin Gene-Related Peptide; Disease Models, Animal; Dynorphins; Endothelin Receptor Antagonists; Endothelin-1; Ganglia, Spinal; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Mice; Mice, Inbred Strains; Pain; Pain Measurement; Pyrrolidines; Receptors, Endothelin; Sarcoma; Sciatic Nerve; Time Factors | 2004 |
Endothelin ET(B) receptor antagonist reduces mechanical allodynia in rats with trigeminal neuropathic pain.
Topics: Animals; Atrasentan; Bosentan; Drug Therapy, Combination; Endothelin B Receptor Antagonists; Endothelin-1; Male; Pain; Pain Threshold; Pyrrolidines; Pyrrolidinones; Rats; Rats, Wistar; Sulfonamides; Time Factors; Trigeminal Neuralgia | 2006 |
ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain.
Topics: Analgesics, Non-Narcotic; Animals; Atrasentan; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Endothelin Receptor Antagonists; Humans; Male; Pain; Pain Measurement; Physical Stimulation; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Stereoisomerism; Vasoconstrictor Agents | 2000 |